BRPI0506537A - compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos - Google Patents

compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos

Info

Publication number
BRPI0506537A
BRPI0506537A BRPI0506537-2A BRPI0506537A BRPI0506537A BR PI0506537 A BRPI0506537 A BR PI0506537A BR PI0506537 A BRPI0506537 A BR PI0506537A BR PI0506537 A BRPI0506537 A BR PI0506537A
Authority
BR
Brazil
Prior art keywords
compounds
methods
disturbed
membranes
bind
Prior art date
Application number
BRPI0506537-2A
Other languages
English (en)
Inventor
Ilan Ziv
Anat Shirvan
Original Assignee
Nst Neurosurvival Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nst Neurosurvival Technologies filed Critical Nst Neurosurvival Technologies
Publication of BRPI0506537A publication Critical patent/BRPI0506537A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSTOS QUE SE LIGAM A MEMBRANAS PERTURBADAS E MéTODOS DE USO DOS MESMOS". A presente invenção se relaciona a compostos que se ligam seletivamente a células sofrendo perturbações e alterações da sua organização de membrana de plasma normal, tais como células sofrendo apoptose ou plaquetas ativadas. A invenção provê métodos de utilização dos ditos compostos na prática médica, para propósitos terapêuticos e de diagnóstico.
BRPI0506537-2A 2004-01-15 2005-01-16 compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos BRPI0506537A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53649304P 2004-01-15 2004-01-15
US53728904P 2004-01-20 2004-01-20
US10/799,586 US7270799B2 (en) 2004-01-15 2004-03-15 Perturbed membrane-binding compounds and methods of using the same
PCT/IL2005/000055 WO2005067388A2 (en) 2004-01-15 2005-01-16 Perturbed membrane-binding compounds and methods of using the same

Publications (1)

Publication Number Publication Date
BRPI0506537A true BRPI0506537A (pt) 2007-02-27

Family

ID=34753699

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506537-2A BRPI0506537A (pt) 2004-01-15 2005-01-16 compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos

Country Status (11)

Country Link
US (2) US7270799B2 (pt)
EP (1) EP1729820A4 (pt)
JP (2) JP5089989B2 (pt)
KR (1) KR101203501B1 (pt)
CN (1) CN101948380A (pt)
AU (1) AU2005204501B2 (pt)
BR (1) BRPI0506537A (pt)
CA (1) CA2553304A1 (pt)
MX (1) MXPA06007987A (pt)
NZ (1) NZ548991A (pt)
WO (1) WO2005067388A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4695591B2 (ja) * 2003-06-18 2011-06-08 アポセンス リミテッド アポトーシス細胞を選択的に標的化する方法、および、それらに用いられる低分子物質リガンド
US7947253B2 (en) * 2004-01-15 2011-05-24 Aposense Ltd. Perturbed membrane-binding compounds and methods of using the same
BRPI0718055A2 (pt) * 2006-11-01 2013-11-05 Bayer Schering Pharma Ag Ácido l-glutâmico marcado com (f-18), l-glutamina maracada com (f-18), seus derivados e seu uso, bem como processos para sua preparação
JP2010517939A (ja) * 2007-01-04 2010-05-27 アポセンス リミテッド 細胞の検出のための化合物および方法
WO2009109798A2 (en) * 2008-03-07 2009-09-11 Universität Ulm Precursors of lipid metabolism for the diagnosis and treatment of cancer
KR20110066927A (ko) 2008-09-05 2011-06-17 임페리얼 이노베이션스 리미티드 생체 내 영상화제로서 사용하기 위한 이사틴 유도체
WO2010150255A1 (en) 2009-06-25 2010-12-29 Aposense Ltd. Conjugates of cytotoxic drugs
RU2421226C1 (ru) * 2009-12-31 2011-06-20 Государственное научное учреждение Всероссийский научно-исследовательский институт генетики и разведения сельскохозяйственных животных Российской академии сельскохозяйственных наук Комплекс для доставки веществ в клетки
US8530444B2 (en) 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
US20120029223A1 (en) * 2010-07-27 2012-02-02 Gad Friedman Method for production of substituted alkyl malonic esters and derivatives thereof
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
ES2574956T3 (es) 2011-09-26 2016-06-23 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
ES2971646T3 (es) 2011-09-26 2024-06-06 Preanalytix Gmbh Estabilización y aislamiento de ácidos nucleicos extracelulares
EP2833877A4 (en) * 2012-04-03 2015-11-25 Aposense Ltd NEW TARGETING AGENTS FOR DIAGNOSTIC AND THERAPEUTIC INDICATIONS
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
WO2014146782A1 (en) 2013-03-18 2014-09-25 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
CN114457068B (zh) 2015-11-20 2025-03-14 普瑞阿那利提克斯有限公司 用于稳定细胞外核酸的已灭菌组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167366B (pt) * 1972-09-06 1975-09-27
US4187381A (en) * 1973-08-06 1980-02-05 Hoffmann-La Roche Inc. 16-Substituted prostaglandins
CH593903A5 (pt) * 1974-06-12 1977-12-30 Sandoz Ag
JPS6034940B2 (ja) * 1980-11-13 1985-08-12 ダイキン工業株式会社 フルオロマロン酸誘導体およびその製法
JPS5939849A (ja) * 1982-08-31 1984-03-05 Daikin Ind Ltd 含フツ素脂肪族基置換アルキル化又はアルケニル化マロン酸エステル又はその誘導体
JPS5939854A (ja) * 1982-08-31 1984-03-05 Daikin Ind Ltd 含フツ素脂肪族基置換マロン酸エステルのエノラ−トイオンのトラツプ方法
EP0103233B1 (en) * 1982-08-31 1987-11-25 Daikin Kogyo Co., Ltd. A method to trap the enolate ion of the malonic acid or its derivatives
GB9512546D0 (en) * 1995-06-20 1995-08-23 Bnfl Fluorchem Ltd A process for the preparation of esters
IL145210A (en) 2000-12-06 2011-12-29 Aposense Ltd Use of pmbc in the preparation of an agent for the selective binding of cells, a method for the detection of apoptosis and a pharmaceutical composition for the treatment of a disease characterized by the presence of apoptosis in cells, tissues or cellular structures

Also Published As

Publication number Publication date
WO2005067388A3 (en) 2005-09-01
US20080014148A1 (en) 2008-01-17
KR101203501B1 (ko) 2012-11-21
MXPA06007987A (es) 2007-01-26
KR20070028312A (ko) 2007-03-12
AU2005204501B2 (en) 2010-02-25
JP2012140424A (ja) 2012-07-26
US7270799B2 (en) 2007-09-18
US20050158239A1 (en) 2005-07-21
NZ548991A (en) 2010-05-28
EP1729820A2 (en) 2006-12-13
AU2005204501A1 (en) 2005-07-28
CN101948380A (zh) 2011-01-19
EP1729820A4 (en) 2009-11-11
US7670590B2 (en) 2010-03-02
WO2005067388A2 (en) 2005-07-28
CA2553304A1 (en) 2005-07-28
JP5089989B2 (ja) 2012-12-05
JP2007523059A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0506537A (pt) compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
EA202091999A3 (ru) Применение ингибиторов dpp iv
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0808164B8 (pt) proteína de actriib variante, proteína de fusão de actriib e preparações farmacêuticas compreendendo as mesmas
WO2009057165A8 (en) Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithelial regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
NO20080084L (no) Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
BRPI0511477A (pt) compostos e composições como moduladores de ppar
FR2884717B1 (fr) Erythrocytes renfermant de l'arginine deiminase
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
WO2005046570A3 (en) Human stem cell materials and methods
WO2010034015A3 (en) Modulating the alternative complement pathway
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
BR112014014869A2 (pt) derivados de sulfonilaminopirrolidinona, sua preparação e sua aplicação terapêutica
CL2008001719A1 (es) Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas.
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
AR029155A1 (es) Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APOSENSE LTD. (IL)

Free format text: NOME ALTERADO DE: NST NEUROSURVIVAL TECHNOLOGIES LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2289 DE 18/11/2014.